Skip to main content
. 2016 Apr 12;173(6):884–895. doi: 10.1111/bjh.14014

Table 3.

Clinical response in patients receiving the highest tolerated dose and the lowest administered dose of carfilzomib.a

  20/56 mg/m2 (PX‐171‐007) (N = 11) 15 or 15/20 mg/m2 (PX‐171‐005) (N = 18)
Responders
(≥ PR) 		64%
(n = 7) 		11%
(n = 2)
Non‐responders
(SD + PD) 		36%
(n = 4) 		89%
(n = 16)

PD, progressive disease; PR, partial response; SD, stable disease.

a

Patients received carfilzomib at a dose of 15 or 20 mg/m2 on days 1 and 2 and a target dose of 56 or 20 mg/m2 on days 8, 9, 15 and 16 in trials PX‐171‐007 and PX‐171‐005, respectively. Some patients in PX‐171‐005 did not step up to their target dose (e.g. from 15 to 20 mg/m2) and continued to receive 15 mg/m2. Patient responses were determined using International Myeloma Working Group criteria (Badros et al, 2013; Papadopoulos et al, 2013).